You are here: Industry Insights > NAFLD

News List

Molecular Stethoscope Announces Publication of its NAFLD/NASH Study in the American Journal of Physiology - Gastrointestinal and Liver Physiology prnasia
February 23, 2021
Molecular Stethoscope, Inc., a precision medicine biotechnology company, announces publication of its human proof-of-concept study describing the stratification of NAFLD/NASH patients with clinically relevant and advanced liver fibrosis using the ...
Zydus gets DCGI approval for Saroglitazar Mg to treat non-alcoholic fatty liver disease expresspharma
December 31, 2020
Saroglitazar Mg is already approved for the treatment of type-2 diabetes and NASH.
‘Concerning’ levels of non-alcoholic fatty liver disease among young people pharmatimes
April 16, 2019
A new study has shown an alarmingly high prevalence of non-alcoholic fatty liver disease (NAFLD) amongst……
ChemomAb Doses First Patient in Phase 1b Clinical trial of CM-101 americanpharmaceuticalreview
January 11, 2019
ChemomAb announced dosing of the first patient in a Phase 1b repeated dose clinical trial with CM-101 in non-alcoholic fatty liver disease (NAFLD) patients....
BASF launches first dedicated product to help patients with NAFLD in the US cphi-online
February 26, 2018
BASF's Hepaxa is the first product in the US specifically designed to address a buildup of fat in the liver in NAFLD patients.
Boehringer Ingelheim Initiates Phase IIa Study of Compound Acquired from Pharmaxis americanpharmaceuticalreview
August 25, 2017
Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NASH with BI 1467335 (formerly known as PXS-4728A), acquired from Pharmaxis in May 2015.